title: Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
abstract: The aim of the study is to investigate the prevalence of high-risk human papillomavirus (hr-HPV) genotypes among Han women with high-grade cervical lesions in Beijing, China.Cervical cell specimens from patients with histopathologically confirmed cervical lesions at 7 hospitals in Beijing were examined with a validated HPV kit for 13 hr-HPV genotypes during the study period. The patients were divided into a low-grade cervical lesions group (cervical intraepithelial neoplasia grade 1, CIN1) and a high-grade cervical lesions group (CIN2+, including cervical intraepithelial neoplasia grade 2, CIN2; cervical intraepithelial neoplasia grade 3, CIN3; squamous cervical cancer, SCC; and adenocarcinoma of the cervix, ACC) based on the histopathology results.A total of 2817 eligible patients were enrolled, including 610 cases identified as CIN1 and 2207 as CIN2+. The hr-HPV positive rates in the CIN1 and CIN2+ groups were 78.2% (477/610) and 93.3% (2060/2207), respectively. The most frequently detected genotypes were HPV16, 58, 52 and18 in the CIN1 group and HPV16, 58, 33, and 52 in the CIN2+ group, in descending order of prevalence. In addition, the prevalence of HPV18 among the patients with ACC was 28.6% (14/49), significantly >7.2% (54/752) prevalence among the SCC patients (P < 0.001). Additionally, significantly more women in the CIN2+ group had multiple infections compared with those in the CIN1 group (38.1% and 24.9%, respectively; P < 0.001). However, as the cervical lesion grade increased, the prevalence of multiple hr-HPV infections gradually deceased to 44.2% in the CIN2 patients, 36.7% in the CIN3 patients, and 35.3% in the cervical cancer (CC) patients, which included SCC and ACC patients. In cases of multiple hr-HPV infections in the CIN2+ group, double infections accounted for ∼76.6%, and HPV16+58, HPV16+52, and HPV16+18 were the most common combinations, in descending order. The most frequent combination for triple infections was HPV16+58+31, with a rate of 4.2%. The highest positive rate occurred in the ≤24 year-old group for all types of cervical lesions.The prevalence of HPV genotypes in the targeted population with high-grade cervical lesions differs from that of other countries. This information could be helpful for the prevention of CC in Beijing, China.
authors.affiliation: From the Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University (MX, QX, HG, YB, ZZ); and Department of Obstetrics and Gynecology, the General Hospital of the People's Liberation Army, Beijing, China (HL).
authors.forename: Meizhu
authors.initials: M
authors.lastname: Xiao
authors.forename: Qiuxiang
authors.initials: Q
authors.lastname: Xu
authors.forename: Hongyan
authors.initials: H
authors.lastname: Li
authors.forename: Huiqiao
authors.initials: H
authors.lastname: Gao
authors.forename: Yachun
authors.initials: Y
authors.lastname: Bie
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000821:virology; D000328:Adult; D000368:Aged; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D002681:China / Q000453:epidemiology; D005260:Female; D005838:Genotype; D052162:Human papillomavirus 16 / Q000235:genetics; D052161:Human papillomavirus 18 / Q000235:genetics; D006801:Humans; D008875:Middle Aged; D018307:Neoplasms, Squamous Cell / Q000473:pathology / Q000821:virology; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000473:pathology / Q000821:virology*; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000821:virology; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000473:pathology* / Q000821:virology
references.citation: Int J Gynecol Pathol. 1993 Apr;12(2):186-92
references.pmid: 8463044
references.citation: Cancer Lett. 2003 Aug 20;198(2):187-92
references.pmid: 12957357
references.citation: Am J Obstet Gynecol. 2012 Jan;206(1):46.e1-46.e11
references.pmid: 21944226
references.citation: Cancer Causes Control. 2009 Nov;20(9):1705-13
references.pmid: 19705288
references.citation: Wien Klin Wochenschr. 2013 Oct;125(19-20):591-9
references.pmid: 24043265
references.citation: Cancer Genet Cytogenet. 2008 Apr 1;182(1):12-7
references.pmid: 18328945
references.citation: Int J Cancer. 2002 Jul 20;100(3):327-31
references.pmid: 12115548
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: J Clin Virol. 2014 May;60(1):44-9
references.pmid: 24630483
references.citation: Lancet. 2009 Jul 25;374(9686):301-14
references.pmid: 19586656
references.citation: Int J Gynecol Cancer. 2009 Jul;19(5):919-23
references.pmid: 19574785
references.citation: Int J Cancer. 2008 Oct 15;123(8):1864-70
references.pmid: 18661520
references.citation: PLoS One. 2014 Sep 17;9(9):e107573
references.pmid: 25229350
references.citation: J Med Virol. 2014 Nov;86(11):1937-43
references.pmid: 25132373
references.citation: N Engl J Med. 2015 Feb 19;372(8):711-23
references.pmid: 25693011
references.citation: Br J Cancer. 2009 Nov 3;101(9):1635-40
references.pmid: 19862002
references.citation: Ann Oncol. 2008 Jul;19 Suppl 5:v48-51
references.pmid: 18611900
references.citation: Int J Gynecol Cancer. 2013 May;23(4):730-4
references.pmid: 23446379
references.citation: Br J Cancer. 2008 Jul 22;99(2):230-8
references.pmid: 18612311
references.citation: J Natl Cancer Inst. 2006 Mar 1;98(5):303-15
references.pmid: 16507827
references.citation: Lancet Oncol. 2010 Nov;11(11):1048-56
references.pmid: 20952254
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2655-64
references.pmid: 20719907
references.citation: Clin Microbiol Infect. 2011 Jun;17(6):941-6
references.pmid: 21040156
references.citation: Cancer Epidemiol. 2013 Dec;37(6):939-45
references.pmid: 24210584
references.citation: Vaccine. 2008 Aug 19;26 Suppl 10:K1-16
references.pmid: 18847553
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):863-5
references.pmid: 19273486
references.citation: Gynecol Oncol. 2012 Feb;124(2):281-5
references.pmid: 22036987
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Clin Chim Acta. 2013 Jan 16;415:297-301
references.pmid: 23148995
references.citation: J Gynecol Oncol. 2009 Jun;20(2):72-6
references.pmid: 19590717
references.citation: Int J Gynaecol Obstet. 2012 Dec;119(3):257-61
references.pmid: 22999251
references.citation: J Clin Oncol. 2001 Apr 1;19(7):1906-15
references.pmid: 11283122
references.citation: J Natl Cancer Inst. 2000 Mar 15;92(6):464-74
references.pmid: 10716964
references.citation: Obstet Gynecol. 2011 Dec;118(6):1222-1229
references.pmid: 22105250
references.citation: J Med Virol. 2011 Jun;83(6):1034-41
references.pmid: 21503917
references.citation: Int J Gynecol Cancer. 2010 Jan;20(1):147-53
references.pmid: 20130516
references.citation: Jpn J Clin Oncol. 2014 Oct;44(10):910-7
references.pmid: 25156680
references.citation: Int J Gynaecol Obstet. 2011 Feb;112(2):131-4
references.pmid: 21092957
references.citation: J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
references.pmid: 7791229